Will screening mammography in the east do more harm than good? by Thach, TQ et al.
Title Will screening mammography in the east do more harm thangood?
Author(s) Leung, GM; Lam, TH; Thach, TQ; Hedley, AJ
Citation Journal of Epidemiology and Community Health, 2001, v. 55 n.suppl. 1, p. A34, abstract no. 130
Issued Date 2001
URL http://hdl.handle.net/10722/43573
Rights Creative Commons: Attribution 3.0 Hong Kong License
Screening
127 EARLY DISCHARGE OF LOW-RISK WOMEN FROM
CERVICAL SCREENING
D. Ogilvie1. 1Department of Public Health, Lanarkshire Health Board.
Background: The Scottish Cervical Screening Programme currently
oVers three-yearly screening to all women between the ages of 20 and
60, irrespective of their underlying risk of disease or their previous
screening history. However, previous studies have indicated that well-
screened women over the age of 50 are likely to be at low risk of cer-
vical neoplasia. This study aimed to explore the implications of
discharging these women from screening in a typical area of Scotland.
Methods: 1. Case-control study of the screening histories of women
with and without screen-detected cervical neoplasia between ages 50
and 59 in Lanarkshire. 2. Cross-sectional study of the prevalence of
adequate screening histories among women currently aged 50 in Lan-
arkshire. 3. Use of routine screening programme statistics to estimate
the eVects of introducing an early discharge policy.
Results: 1. Women reaching the age of 50 with two recent, consecu-
tive, negative smears had reduced odds of screen-detected neoplasia
in the subsequent decade. 2. The estimated odds ratio for all screen-
detected neoplasia was 4.4 (95% confidence interval 1.6–13.2,
p=0.002). 3. The estimated odds ratio for screen-detected high-grade
squamous neoplasia was 17.0 (95% confidence interval 2.4–243.0,
p=0.0004). 4. 54.0% (95% confidence interval 47.9%-59.9%) of
screening participants currently aged 50 fulfilled the definition of
adequate screening. 5. Discharging these women might be expected to
reduce screening workload by approximately 10%, but those
discharged would acquire an increased risk of cervical neoplasia—
predominantly low-grade or glandular neoplasia—as a result.
Conclusion: It is possible to identify a low-risk group within the
screened population using routinely-available records. This type of
information could be used to inform participative decision-making
about individual women’s need for screening, or to target the screen-
ing programme more closely on those with the greatest capacity to
benefit from it.
128 TWENTY YEAR ANALYSIS OF BENEFITS AND HARMS
FROM CERVICAL SCREENING
A. E. RaZe1, B. Alden1, M. Brett2, P. J. Babb3, M. Quinn3. 1Department of
Public Health Medicine, Avon Health Authority, Bristol; 2Department of Cellu-
lar Pathology, Southmead Hospital, Bristol; 3National Cancer Registration
Bureau, OYce for National Statistics, London.
The National Screening Committee and General Medical Council
advise giving information about benefits and harms to enable
informed choice about whether to participate in screening. Infor-
mation about cervical screening has emphasised that screening saves
lives, but has not explained that screen-detected abnormality is com-
mon and in most cases represents self-limiting cell change. Nor has
the fact that missed cases and incurable cases are inevitable despite
screening been successfully conveyed. Data on which to base
information about the diVerent screening outcomes is lacking.
We analysed records for women screened in Bristol from 1976 to
1996 to determine cumulative incidence for cytological and histologi-
cal abnormality of the cervix. Using OYce for National Statistics
mortality data we modelled expected numbers of deaths from cancer
of the cervix for this cohort of women a) assuming that pre-screening
death rates and trends had continued, and b) assuming that cohort
reductions in cervix cancer deaths had taken place equivalent to those
observed for England and Wales as a whole.
Amongst 214,582 women with a recent test result there were
33,522 (15.6% of the total tested) who had ever had abnormal cytol-
ogy, and 11,656 (5.4%) who had ever had abnormal histology during
the twenty years from April 1976 to March 1996. Trends for each
birth cohort and for each grade of abnormality yield information
about diagnostic trends, reversibility of lesions, and rising incidence.
The mortality modelling is near completion, and will enable numbers
with screen-detected abnormality to be put in context against
numbers who would have developed cancer were it not for screening.
The indication is that at least 90% of women with abnormal results
would—without any intervention - have remained free of cervical can-
cer by the age of 70. These results should help to achieve better pub-
lic and professional understanding of the consequences of screening.
129 RELATIONSHIP BETWEEN MENOPAUSE, USE OF
HORMONE REPLACEMENT THERAPY AND THE
SENSITIVITY AND SPECIFICITY OF SCREENING FOR
BREAST CANCER
E. Banks1, V. Beral1, D. Bull1, G. Reeves1. 1Imperial Cancer Research Fund
Cancer Epidemiology Unit, Gibson Building, RadcliVe Infirmary, Oxford
OX2 6HE, UK.
Introduction: Previous studies suggest a detrimental eVect of use of
HRT on breast cancer screening but have been unable to account for
important confounding factors.
Methods: A total of 124,886 women participating in the Million
Women Study at 10 NHS screening centres from June 1996 to March
1998 completed a study questionnaire immediately prior to screening.
They were followed through the breast screening programme for
recall to assessment following screening and screen-detected cancer,
and through regional cancer registries for the occurrence of breast
cancer in the interval following screening.
Results: Overall, 5,367 (4.3%) women were recalled to assessment.
Among women who had never used HRT, the adjusted proportion
recalled to assessment with no subsequent diagnosis of breast cancer
(“false positive recall”) was 4.7% (95% CI 4.1–5.3%) in premeno-
pausal women, 4.2% (3.7–4.7%) in perimenopausal women and
2.5% (2.3–2.7%) in postmenopausal women. Postmenopausal
women who were currently using HRT had a significantly elevated
rate of false positive recall of 4.0% (3.7–4.3%), compared to 2.5%
among never users. Among current users the rate of false positive
recall increased with increasing duration of use, however the eVect of
HRT did not diVer significantly according to the type of preparation
used or the dose of oestrogen. Former users of HRT had a
significantly elevated risk of false positive recall (3.0%, 2.7–3.4%)
compared to never users. The risk appeared to diminish following
cessation of use and 5 years after ceasing use the rate of false positive
recall did not diVer significantly from that in never users. Overall, use
of HRT could account for around 20% of the total cases of false posi-
tive recall in the NHSBSP annually. Preliminary data indicate that
women who are currently using HRT have around double the rate of
interval cancer compared to women who have never used HRT.
130 WILL SCREENING MAMMOGRAPHY IN THE EAST DO
MORE HARM THAN GOOD?
G. M. Leung1, T. H. Lam1, T. Q. Thach1, A. J. Hedley1. 1Department of
Community Medicine, The University of Hong Kong, Hong Kong.
Background: Breast cancer screening by mammography has become
routine practice in many Western countries, but there are no data
about its eYcacy in Asian women. We systematically reviewed the evi-
dence for population-based screening for breast cancer and examined
the applicability of these results to a Chinese population.
Methods: Primary reports for the meta-analysis were identified by a
search of MEDLINE and the Cochrane Library. Information on
breast cancer incidence and mortality was collected from the
International Agency for Research on Cancer and the Hong Kong
Cancer Registry. Outcome measures included breast cancer-related
mortality, the number needed to screen (NNS) to prevent one death,
and the positive predictive value (PPV) of mammography.
Results: We identified eight clinical trials conducted in Western
women. The pooled relative risk for breast cancer-related death in the
screened group was 0.82 (95% confidence interval = 0.72, 0.93).
When applied to Hong Kong this translates into an NNS of 1,447
healthy women screened annually for 10 years to prevent one death,
assuming the relative risk reduction is independent of the baseline
risk. The PPV of mammography was between 1.8% and 13.4%.
Therefore, for 100,000 Hong Kong Chinese women aged 50 or over
screened annually for 10 years we would expect 8,980 false positive
cases, 134 of them would sustain a biopsy-related complication. Only
69 breast cancer-related deaths would be avoided, assuming trial con-
ditions and 100% uptake and follow-up.
Conclusions: There is insuYcient evidence to justify population-
based breast cancer screening by mammography for women in Hong
Kong and other Asian populations with low breast cancer prevalence.
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